|
Investor presentation
|
24 May 2023 at 8:45am
|
|
PXS Announces Encouraging Results from Phase 1c Scar Study
|
23 May 2023 at 5:00pm
|
|
Trading Halt
|
22 May 2023 at 9:20am
|
|
Investor Presentation - Quarterly Briefing
|
28 April 2023 at 11:05am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 April 2023 at 8:55am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 April 2023 at 8:55am
|
|
PXS Quarterly Update and Investor Briefing
|
21 April 2023 at 9:10am
|
|
After FDA Review PXS Accelerates Plans for Combination Study
|
12 April 2023 at 9:30am
|
|
Ceasing to be a substantial holder
|
31 March 2023 at 7:10pm
|
|
Pharmaxis Drug Study Published in Nature Communications
|
23 March 2023 at 9:50am
|
|
Becoming a substantial holder
|
22 March 2023 at 7:45pm
|
|
Change in substantial holding
|
21 March 2023 at 5:25pm
|
|
Application for quotation of securities - PXS
|
20 March 2023 at 9:45am
|
|
Application for quotation of securities - PXS
|
16 March 2023 at 9:35am
|
|
Change in substantial holding
|
13 February 2023 at 5:30pm
|
|
PXS Securities Trading Policy - Updated 10 Feb 2023
|
13 February 2023 at 9:15am
|
|
Half Yearly Report and Accounts
|
10 February 2023 at 3:50pm
|
|
Investor Presentation
|
6 February 2023 at 1:20pm
|
|
Investor Presentation
|
31 January 2023 at 11:30am
|
|
Quarterly Activities Report
|
31 January 2023 at 9:20am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 January 2023 at 9:20am
|
|
Quarterly Shareholder Update and Investor Briefing
|
23 January 2023 at 10:35am
|
|
Application for quotation of securities - PXS
|
23 January 2023 at 8:50am
|
|
Initial Director's Interest Notice
|
16 January 2023 at 9:00am
|
|
Director Appointment/Resignation
|
16 January 2023 at 9:00am
|
|
Pharmaxis Receives $5m R&D Tax Incentive
|
9 January 2023 at 10:15am
|
|
Application for quotation of securities - PXS
|
22 December 2022 at 10:45am
|
|
Pharmaxis Skin Scarring Study Fully Recruited
|
21 December 2022 at 10:35am
|
|
Initial Director's Interest Notice
|
14 December 2022 at 1:40pm
|
|
Pharmaxis Appoints Dr Simon Green as Director
|
14 December 2022 at 1:35pm
|
|
Change in substantial holding
|
14 December 2022 at 9:20am
|
|
PXS Drug Profiled American Society of Hematology Conference
|
12 December 2022 at 9:59am
|
|
Application for quotation of securities - PXS
|
12 December 2022 at 9:20am
|
|
Change in substantial holding
|
8 December 2022 at 5:10pm
|
|
Becoming a substantial holder
|
7 December 2022 at 5:30pm
|
|
Change in substantial holding
|
6 December 2022 at 6:40pm
|
|
Section 708(5)(e) Notice
|
5 December 2022 at 9:45am
|
|
Ceasing to be a substantial holder
|
2 December 2022 at 5:25pm
|
|
Change of Director's Interest Notice
|
2 December 2022 at 3:20pm
|
|
Change of Director's Interest Notice
|
2 December 2022 at 3:20pm
|
|
Change of Director's Interest Notice
|
2 December 2022 at 3:15pm
|
|
Notification regarding unquoted securities - PXS
|
2 December 2022 at 2:55pm
|
|
Application for quotation of securities - PXS
|
2 December 2022 at 2:35pm
|
|
Change of Director's Interest Notice
|
29 November 2022 at 12:45pm
|
|
Notification regarding unquoted securities - PXS
|
29 November 2022 at 12:30pm
|
|
Results of Meeting
|
29 November 2022 at 12:15pm
|
|
Chairman's Address to Shareholders
|
29 November 2022 at 9:35am
|
|
CEO Presentation to 2022 AGM
|
29 November 2022 at 9:25am
|
|
Application for quotation of securities - PXS
|
23 November 2022 at 2:40pm
|
|
Investor Presentation
|
9 November 2022 at 11:55am
|
Pharmaxis Ltd